Understanding biology

to better treat cancer

Exemplary science

creating innovative medicines

A shared commitment

to improving patient outcomes

We Are Focused


on discovering and developing novel therapeutics directed to fundamental biologic pathways thought to drive cancer's growth, resistance, recurrence and metastases in order to improve the treatment of solid tumor cancers.

Productive Research Capabilities


Expertise in cancer biology, platform drug discovery technologies and sophisticated antibody engineering know-how have combined to generate a large internally discovered oncology pipeline

Multiple
Shots on Goal
 


Eight distinct clinical-stage anti-cancer drugs plus ongoing drug discovery efforts tackling challenging and unique targets sets us up for huge potential successes

Financial Strength and Value Creation


Collaborations with partners provide validation of our scientific approach, access to commercial expertise and funding to advance our pipeline and enable strategic company growth

Pipeline

  • demcizumab
  • tarextumab
  • vantictumab
  • ipafricept
  • anti-RSPO3
  • navicixizumab
  • brontictuzumab
  • anti-TIGIT
  • GITRL-Fc trimer
  • multiple preclinical I/O candidates
Preclinical Phase 1 Phase 2

Latest News

NASDAQ: OMED

Change
Day High
Day Low
Volume

Delayed at least 20 minutes. Provided by eSignal.